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Fatty acid metabolism is altered in colorectal cancer (CRC). We aimed to investigate incorporation of dietary n-6 and n-3
polyunsaturated fatty acids (PUFAs) into plasma phospholipids (PLs), tumour tissue, and normal mucosa in young CRC patients.
We also aimed to study differences in PUFA composition between tumour and normal mucosa, and PUFA status associated with
cancer stage. Sixty-five CRC patients younger than 55 years were included in a multicenter study. We assessed dietary fatty acid
composition by food-frequency questionnaire. Fatty acid composition in plasma PL (n = 65) and tumour and normal colonic
biopsies (n = 32) were analysed by gas chromatography. We observed a significant correlation for docosahexaenoic acid (DHA)
between dietary intake and concentration in plasma PL (weight%) (r = 0.42; P = 0.001), but not for any n-6 PUFA. Tissue
concentrations of arachidonic acid, eicosapentaenoic acid, and DHA (weight%) were 1.7–2.5 times higher in tumour than normal
mucosa (P ≤ 0.001). Concentrations of n-3 and n-6 PUFA in plasma PL and tissues were not related to Duke’s stage, although
patients with more severe cancer stage reported higher intake of n-3 PUFA. In conclusion, we found accumulation of the long-
chained n-3 and n-6 PUFA in tumour tissue in young CRC patients.
1. Introduction
The association between dietary fat and risk of cancer has
been extensively investigated, and the composition of poly-
unsaturated fatty acids (PUFA) in diet seems to be of par-
ticular importance [1]. However, the effects of single dietary
n-3 and n-6 PUFA, and the ratio n-3/n-6 PUFA are not
completely clear. The majority of case-control studies seem
to support a protective role of dietary n-3 PUFA and n-3/n-
6 PUFA ratio [2–4], but these associations have been con-
firmed by only one cohort study [5], and have been contra-
dicted or not found by several cohort studies [6–8]. Studies
on serum and erythrocyte membrane fatty acid composition,
regarded as biomarkers for fatty acid intake, mainly support
a protective role for the very long-chained n-3 PUFA docosa-
hexaenoic acid (DHA) [8–11]. Abnormalities in plasma
PUFA composition may also be interpreted as metabolic
changes in CRC patients [12]. Dietary and biomarker studies
have not established the role of n-6 PUFA in CRC. Based
on changes in n-3 and n-6 PUFA expression in colorectal
tumours, compared to normal mucosal tissue [13, 14], also
found at early stages of adenomas [13], it seems obvious
that patients with CRC have an altered PUFA metabolism.
Literature on CRC tumour PUFA pattern is sparse, and
previous studies have not concluded on which particular
PUFAs are present in diseased and normal mucosa [13, 14].
However, PUFA pattern in normal mucosal tissue seems to
be similar in CRC patients and healthy subjects [13]. This
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indicates that the changes in mucosal fatty acid pattern are
tumour and normal tissue specific in general CRC patients.
The younger CRC patients may be more genetically
predisposed; their tumour might be expected to be more
aggressive [15] and environmental factors relatively less
pronounced in the etiology of the disease, compared to older
patients. Genetic predisposition is known in patients with
familial adenomatous polyposis (FAP), who may have char-
acteristics more similar to young CRC patients. Our previous
study in FAP patients showed increased concentrations of
arachidonic acid (AA) and DHA, and decreased concentra-
tions of linoleic acid (LA) and α-linolenic acid (ALA) in
plasma phospholipids (PL) [16], opposite to the majority
of findings of protective effect of DHA against development
of colorectal adenomas [9–11, 17]. We therefore hypothesize
that PUFA concentration in plasma phospholipid does not
reflect dietary PUFA in young CRC patients. We further
hypothesize that PUFA composition differs between CRC
tumour tissue and normal colonic mucosal biopsies, thereby
investigating if the fatty acid pattern characteristic for FAP
patients could be observed in the colorectum of CRC
patients. We also wanted to study whether dietary PUFA
intake or concentration of PUFA in plasma PL, tumour, or
normal mucosa were associated with cancer stage (Duke’s
stage).
2. Materials and Methods
2.1. Patients. Eighty-two patients were recruited from seven
hospitals in the South-Eastern region of Norway. Inclusion
criteria were adenocarcinoma of the colon or rectum and
age below 55 years. Exclusion criterion was known familial
syndromes affecting CRC risk including hereditary non-
polyposis colorectal cancer (HNPCC) and FAP. The inclu-
sion period was from December 2003 until April 2009.
2.2. Blood Sampling and Analyses. A blood sample was col-
lected preoperatively and centrifuged within 30min. Plasma
samples were sent to Oslo University Hospital, Rikshospitalet
and stored in −80◦C. The frozen samples were sent on
dry ice to Vitas AS, Oslo, Norway, where they were stored
at −20◦C until analyses. Fatty acid contribution in plasma
phospholipid fraction (PL) was quantitatively determined as
follows: plasma samples were thawed overnight at 4◦C and
vortexed for 5 sec. Dichloromethane in methanol was added
to plasma and the internal standard (1,2 diheptadecaonyl-
sn-glycero-3-phosphatidylcholine). After shaking and cen-
trifugation, the supernatant was transferred into new glasses
and washed in 0.9% saline solution. Lower phase was
transferred to solid phase extraction columns. Polar lipids
were washed out with dichloromethane/isopropanol and
Methyl tert-butyl ether (MTBE)/formic acid. Phospholipids
were eluted with methanol. After evaporation to dryness in a
vacuum centrifuge, phospholipids were transmethylated by
sodium methoxide, and fatty acid methyl esters (FAMEs)
were extracted to hexane before gas-chromatographic (GC)
analysis. The GC analysis was performed on a 7683B GCwith
a split/splitless injector, a 7683B automatic liquid sampler,
and flame ionization detection (Agilent Technologies, Palo
Alto, CA, USA). Separations were performed on a 30m SP-
2380 column (Supelco, Sigma-Aldrich, St. Louis, MO, USA).
2.3. Tumour and Normal Mucosa Samples and Analyses.
Tumour and normal mucosa tissue samples, at least 2 ×
1 × 0.5 cm in size, were collected immediately after resection
of the specimen, prepared with RNA-later, transported, and
stored dry in−80◦C until analysis. The normal mucosa sam-
ple was taken from a normal appearing part of the resected
specimen, at least 20 cm from the cancer. The frozen samples
were sent on dry ice to Vitas AS, Oslo, Norway, where
tissue fatty acid contribution was determined as follows:
approximately 10mg tissue was directly methylated with 3N
MeOH HCl, first 30 minutes at 70◦C on an ultrasonic bath,
and later at 80◦C on a thermoblock with 500 rpm. FAMEs
were extracted with hexane, and the samples were subse-
quently neutralized with KOH in water. After mixing and
centrifuging the hexane phase was injected into the GC-FID.
The GC analysis was performed similarly as for plasma PL.
2.4. Dietary Intake. The patients were contacted postopera-
tively by telephone and invited to give dietary and lifestyle
data. Dietary intake was assessed by a validated self-filled
food-frequency questionnaire (FFQ) [18], designed to cover
as much of the total diet as possible. Questions were related
to habitual frequency of consumption and the amount
of foods eaten during the one-year period prior to CRC
diagnosis. Dietary supplements, such as cod liver oil, fish
oil capsules, and vitamin and mineral supplements, were
included. The FFQ was mailed to the participants and filled
in at home. After returning of the questionnaire by mail,
the participants were contacted by a dietitian by telephone,
and filling of the FFQ was checked. Dietary intakes were
calculated by using a database and a software system
developed at the Department of Nutrition, University of
Oslo (KOSTBEREGNINGSSYSTEM, version 3.2; University
of Oslo, Oslo, Norway).
In the previously developed lifestyle questionnaire [19],
participants were asked to describe their smoking status by
detailed questions on current and lifetime smoking status.
Participants were asked to assess their last weight before
CRC diagnosis as well as nonvigorous and vigorous physical
activity (minimum 20min at the time). The alternative
frequencies of activity were: never, less than once/week, 1-2
times/week, 3-4 times/week, 5–7 times/week, and more than
7 times/week. The participants were also asked to state their
weekly hours of occupational activity prior to CRC diagnosis,
and possible changes in physical activity and dietary habits
after the diagnosis.
2.5. Ethical Approval. The study protocol was approved by
the Norwegian health authorities and the regional ethics
committee. The study was performed in accordance with
the Helsinki Declaration. Written informed consent was
obtained from all included patients.
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2.6. Statistical Analysis. Continuous variables are expressed
as median values (25th, 75th quartile). Categorical variables
are presented as percentages (%). We tested differences
in fatty acid concentrations between tumour and normal
mucosa by paired, non-parametric Wilcoxon Signed Ranks
Test, and differences in categorical variables between sub-
groups by chi-square statistics. We used Pearson’s correlation
coefficients (r) to test relations between variables. We also
tested correlations between dietary and plasma PL fatty
acids, and between PUFA in plasma PL and normal mucosa
and tumour tissue in analysis stratifying by BMI (<25 and
≥25 kg/m2). P values < 0.05 were considered as statistically
significant. We conducted the statistical analysis using soft-
ware SPSS 15.0 for Windows (SPSS Inc., Chicago, IL, USA).
No corrections were made for multiple comparisons.
3. Results
3.1. Subject Characteristics. A total of 69 patients provided
sufficient dietary data, whereas 79 patients had data on
plasma PL. Totally 65 CRC patients with median age of 47
years (range 27–54 years), and median BMI of 24.8 kg/m2
(range 18.4–43.2 kg/m2), had data on fatty acid composition
in diet and plasma PL. Altogether 32 patients had additional
data on fatty acid composition in tumour and normal
colonic mucosal tissue. Subject characteristics are given in
Table 1. Forty-eight percent of the subjects were overweight
or obese (≥25 kg/m2), whereas six percent of the patients
had low BMI (<20 kg/m2). Thirteen percent of the subjects
reported themselves as current daily smokers, whereas 37
percent reported never having smoked. First or second
degree family history of CRC in 14 percent of the patients
was confirmed by the Cancer Registry of Norway. The
self-reported physical activity level was not associated with
dietary intake of energy or fat, or BMI (not shown).
3.2. Dietary Fat Intake, Correlation with Plasma PL Fatty Acid
Composition. Mean dietary intake of total and saturated fat
was somewhat higher than in the Nordic Nutrition Recom-
mendations [20]. Intakes of total and long-chained marine
n-3 PUFA were in line with the recommendations (Table 2).
Dietary DHA intake and the sum of EPA and DHA intake
correlated positively with the respective concentrations in
plasma PL (r = 0.42, P = 0.001 and r = 0.36, P = 0.003,
resp.). Other n-3 or n-6 PUFA did not show correlation
between diet and plasma PL, but the ratio of n-3/n-6 PUFA
showed a correlation between diet and plasma PL (r = 0.29,
P = 0.02) (Table 2). The correlations did not noticeable
differ between lean and overweight patients (not shown).
3.3. Differences in Plasma PL Composition between Patients
with High and Low Dietary EPA + DHA Intake. When sepa-
rating the CRC patients into low and high dietary EPA+DHA
intake at a median of 0.82 g/day, the patients with intake
above the median had higher plasma PL concentration of
DHA and n-3/n-6 PUFA ratio (P = 0.004 and P =
0.006, resp.), and borderline significantly lower plasma PL
Table 1: Characteristics of the colorectal cancer patients (n = 65)a.
n (%)
Male 35 (54)
Age categories (years)
<40 12 (19)
40–49 30 (46)
50–54 23 (35)
BMI categories (kg/m2)b
<20.0 4 (6)
20.0–24.9 30 (46)
25.0–29.9 24 (37)
30.0+ 7 (11)
Smoking statusc
Never 23 (37)
Ex and occasional 31 (50)
Current 8 (13)
Physical activityc
Low 18 (29)
Middle 28 (45)
High 16 (26)
1st or 2nd degree family history of CRC 9 (14)
Duke’s stage
A 5 (8)
B 22 (34)
C 19 (29)
D 19 (29)
a
Abbreviations are as follows: BMI: bodymass index (kg/m2); CRC: colorec-
tal cancer.
bThree subjects had self-reported height and weight.
cMissing value in three subjects (n = 62).
concentration of LA+AA and ratio of AA/EPA (P = 0.05 for
both) (Table 3).
3.4. Fatty Acids in Tumour and Normal Mucosa. Median con-
centrations of all individual fatty acids of interest differed
significantly between normal mucosa and tumour tissue
(Table 4). Median concentrations of all long-chained n-3 and
n-6 PUFA (C20-22) were higher in tumours than normal
biopsies, whereas concentrations of the C18-chained PUFA
LA and ALA were lower in tumour tissue than normal
mucosa. AA and DHA were higher in tumours than normal
biopsies (7.5 versus 3.5 g/100 g, P = 0.001, and 2.2 versus
1.3 g/100 g, P < 0.001, resp.). The ratio n-3/n-6 PUFA,
but also the ratio AA/EPA were higher in the tumour than
normal tissue (0.15 versus 0.13, P < 0.001 and 12.5 versus
9.7, P = 0.03, resp.) (Table 4).
3.5. Plasma PL Concentration of EPA + DHA and LA + AA
Correlated to n-6 and n-3 PUFA in Tumour Tissue and Normal
Mucosa. There was a significant correlation between plasma
PL concentrations of EPA and DHA (weight%) and the
concentrations of EPA and DHA in normal mucosa and
tumour tissues. These correlations existed both for EPA and
DHA separately, and for the sum of these (Table 5). Also
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Table 2:Median (25th, 75th quartile) dietary intake of fatty acids (g/day and E%) and fatty acid concentrations of plasma phospholipids (PL)
(weight%), Nordic Nutrition Recommendations (NRR) and correlation between diet (g/day) and plasma PL in colorectal cancer patients
(n = 65)a.
Dietary fat intake
NRR Plasma PL (weight %) r
g/day E%
Total fat 90.3 (75.7, 107.5) 33.8 (30.4, 36.9) <30E%
Total saturated fatty acids 33.7 (28.3, 41.1) 12.9 (11.0, 14.0) <10E% 40.2 (39.5, 40.9) 0.23
16:0 (palmitic acid) 16.9 (14.0, 19.4) 6.3 (5.4, 6.9) 27.5 (26.4, 28.9) 0.20
18:0 (stearic acid) 7.9 (6.7, 10.1) 3.1 (2.7, 3.5) 12.5 (11.9, 13.5) −0.05
16:1n-7 (palmitoleic acid) 1.6 (1.4, 1.8) 0.6 (0.5, 0.7) 0.52 (0.46, 0.69) 0.31c
18:1n-9 (oleic acid) 27.3 (22.0, 32.6) 10.1 (8.5, 11.4) 8.5 (7.8, 9.4) 0.20b
20:1n-9 (eicosenoic acid) 0.7 (0.6, 0.9) 0.3 (0.2, 0.3) 0.14 (0.12, 0.16) 0.12
18:2n-6 (linoleic acid) (LA) 15.2 (12.1, 19.5) 5.7 (4.7, 6.7) 20.3 (17.4, 22.0) 0.10
18:3n-3 (α-linolenic acid (ALA) 2.1 (1.8, 2.8) 0.8 (0.7, 0.9) 0.25 (0.21, 0.30) 0.12
20:4n-6 (arachidonic acid) (AA) 0.14 (0.11, 0.18) 0.05 (0.04, 0.06) 9.2 (7.9, 10.7) 0.03
20:5n-3 (eicosapentaenoic acid) (EPA) 0.30 (0.21, 0.43) 0.1 (0.07, 0.18) 1.3 (1.0, 2.2) 0.21
22:6n-3 (docosahexaenoic acid) (DHA) 0.50 (0.38, 0.64) 0.2 (0.13, 0.27) 5.6 (4.7, 6.9) 0.42d
Sum EPA + DHA 0.82 (0.60, 1.04) 0.3 (0.2, 0.4) ≥0.45 g/day 7.2 (5.8, 9.2) 0.36c
Ratio AA/EPA 0.42 (0.35, 0.67) 6.9 (4.8, 9.1) 0.14
Sum n-3 fatty acids (ALA + EPA + DHA) 3.08 (2.55, 3.77) 1.1 (1.0, 1.3) >1E% 7.35 (6.11, 9.38) 0.16
Sum n-6 fatty acids (LA + AA) 15.37 (12.30, 19.80) 5.7 (4.8, 6.8) 30.10 (27.55, 31.65) −0.08
Ratio n-3/n-6 fatty acids 0.19 (0.17, 0.23) 0.25 (0.20, 0.33) 0.29b
Total polyunsaturated fatty acids 18.4 (14.9, 23.4) 7.0 (6.0, 8.0) 5–10E% 37.7 (36.5, 39.2) −0.16
a
Abbreviations are as follows: E%: percent of energy intake; NRR: Nordic Nutrition Recommendations; PL: phospholipids; r: Pearson correlation coefficient.
bSignificant correlation (P < 0.05).
cSignificant correlation (P ≤ 0.01).
dSignificant correlation (P = 0.001).
Table 3: Median (25th, 75th quartile) fatty acid concentrations of plasma phospholipids (PL) (weight%) in colorectal cancer patients
separated by low and high dietary daily EPA + DHA intake (<0.82 and 0.82+ g/day) (n = 65)a.
Fatty acids in plasma PL
(weight%)
Subjects with dietary EPA + DHA
intake <0.82 g/day (n = 32)
Subjects with dietary EPA + DHA
intake 0.82+ g/day (n = 33) P value
18:2n-6 (LA) 21.1 (18.4, 23.6) 19.5 (17.3, 21.4) 0.12
20:4n-6 (AA) 9.4 (7.8, 10.4) 8.9 (7.9, 11.3) 0.96
Sum LA + AA 31.3 (28.7, 32.5) 29.1 (27.5, 31.1) 0.05
20:5n-3 (EPA) 1.2 (1.0, 1.6) 1.6 (1.1, 2.3) 0.06
22:6n-3 (DHA) 5.1 (4.4, 6.3) 6.3 (5.5, 7.6) 0.004
Sum EPA +DHA 6.4 (5.6, 7.7) 7.8 (6.8, 9.6) 0.006
Ratio AA/EPA 7.7 (5.7, 9.6) 5.5 (4.1, 8.0) 0.05
Ratio n-3/n-6 fatty acids 0.21 (0.18, 0.27) 0.27 (0.23, 0.35) 0.006
a
Abbreviations are as follows: AA: arachidonic acid; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; LA: linoleic acid; PL: phospholipids.
the ratio n-3/n-6 PUFA in normal mucosa and tumour
tissue significantly correlated with plasma PL concentration
of EPA + DHA. The significant correlation between plasma
PL concentration of EPA + DHA, and AA concentration in
normal mucosa (r = 0.43, P = 0.02) remained significant
only in overweight patients (r = 0.69, P = 0.005) when
stratifying by BMI groups. Plasma PL concentration of LA +
AA (weight%) correlated positively with LA concentration
in normal mucosa tissue. There were no other correlations
between plasma PL concentration of LA + AA, and tissue
PUFA concentrations, but the ratio of n-3/n-6 PUFA in
normal mucosa was significantly inversely correlated with
plasma PL concentration of LA + AA (Table 5).
3.6. Duke’s Stage Compared to n-3 and n-6 PUFA in Diet,
Plasma PL, and Tissue. Median dietary intake of DHA was
higher in CRC patients with severe Duke’s stage (C + D) as
compared to patients with less severe Duke’s stage (A + B)
(0.56 versus 0.45 g/d, P = 0.02) (Table 6). Further, dietary
ratio of n-3/n-6 PUFA was higher in patients with Duke’s
stage C + D compared to A + B (0.21 versus 0.18, P =
0.007). There were no significant differences in dietary AA
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Table 4: Median (25th, 75th quartile) fatty acid concentrations (weight%) in normal duodenal mucosa and tumour biopsies in colorectal
cancer patients (n = 32).
Normal mucosa (weight%) Tumour tissue (weight%) P value
16:0 (palmitic acid) 20.0 (18.6, 21.6) 18.3 (17.9, 19.6) 0.001
18:0 (stearic acid) 8.1 (5.9, 10.3) 12.5 (11.0, 13.4) <0.001
16:1n-7 (palmitoleic acid) 3.2 (1.9, 4.6) 1.8 (1.4, 2.5) 0.007
18:1n-9 (oleic acid) 33.6 (29.2, 39.6) 23.1 (21.2, 24.8) <0.001
18:2n-6 (linoleic acid) (LA) 13.5 (12.1, 15.5) 12.2 (10.8, 13.4) 0.001
18:3n-3 (α-linolenic acid (ALA) 0.59 (0.43, 0.76) 0.25 (0.15, 0.29) <0.001
20:4n-6 (arachidonic acid) (AA) 3.5 (1.8, 6.4) 7.5 (6.1, 8.2) 0.001
20:5n-3 (eicosapentaenoic acid) (EPA) 0.23 (0.17, 0.52) 0.57 (0.32, 0.85) 0.001
22:6n-3 (docosahexaenoic acid) (DHA) 1.30 (0.93, 1.59) 2.15 (1.67, 2.64) <0.001
Sum EPA + DHA 1.5 (1.1, 2.1) 2.7 (2.1, 3.4) <0.001
Ratio AA/EPA 9.7 (7.9, 17.3) 12.5 (8.5, 20.1) 0.03
Sum n-3 fatty acids (ALA + EPA + DHA) 2.2 (1.8, 2.7) 2.9 (2.3, 3.6) <0.001
Sum n-6 fatty acids (LA + AA) 16.7 (15.2, 21.1) 19.8 (17.2, 20.5) 0.11
Ratio n-3/n-6 fatty acids 0.13 (0.11, 0.15) 0.15 (0.12, 0.18) <0.001
Sum polyunsaturated fatty acids 18.5 (17.2, 23.6) 23.0 (19.3, 24.4) 0.05
Table 5: Correlation between selected polyunsaturated fatty acids and fatty acid ratios in tumour and normal mucosal biopsies and plasma
phospholipids (PL) EPA + DHA and LA + AA concentrations (weight%) in colorectal cancer patients (n = 32)a.
r
normal mucosa (n = 32) tumour tissue (n = 32)
EPA + DHA concentration in plasma PL correlated with tissue concentration of
18:2n-6 (LA) −0.30 0.05
20:4n-6 (AA) 0.43b −0.05
Sum LA + AA 0.15 0.001
20:5n-3 (EPA) 0.44c 0.51c
22:6n-3 (DHA) 0.71d 0.44c
Sum EPA + DHA 0.66d 0.50c
Ratio AA/EPA −0.07 −0.55d
Ratio n-3/n-6 fatty acids 0.77d 0.70d
LA + AA concentration in plasma PL correlated with tissue concentration of
18:2n-6 (LA) 0.50c 0.12
20:4n-6 (AA) −0.22 0.24
Sum LA + AA 0.14 0.25
20:5n-3 (EPA) −0.17 −0.20
22:6n-3 (DHA) −0.33 −0.18
Sum EPA + DHA −0.29 −0.20
Ratio AA/EPA −0.07 0.36b
Ratio n-3/n-6 fatty acids −0.47c −0.42b
a
Abbreviations are as follows: AA: arachidonic acid; DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; LA: linoleic acid; PL: phospholipids; r: Pearson
correlation coefficient.
bSignificant correlation (P < 0.05).
cSignificant correlation (P ≤ 0.01).
dSignificant correlation (P = 0.001).
content or plasma PL concentrations of any n-3 or n-6 PUFA
between the Duke’s stage groups (Table 6). There was no
difference between the Duke’s stage groups in any of PUFA
concentrations or ratios in tumour and normal mucosal
tissue (not shown).
4. Discussion
In the present study of young CRC patients, we found
that dietary intake of total PUFA and marine n-3 fatty
acids EPA and DHA were according to national dietary
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Table 6: Median (25th, 75th quartile) content of selected polyunsaturated fatty acids and ratio n-3/n-6 fatty acids in diet and plasma
phospholipids (PL) in colorectal cancer patients, separated by Dukes stage A + B and C +D (n = 65)a.
Dukes stage
A + B (n = 27) C + D (n = 38) P value
Diet (g/day)
Dietary 20:4n-6 (AA) 0.13 (0.11, 0.15) 0.15 (0.11, 0.20) 0.13
Dietary 20:5n-3 (EPA) 0.26 (0.18, 0.37) 0.34 (0.24, 0.53) 0.10
Dietary 22:6n-3 (DHA) 0.45 (0.33, 0.58) 0.56 (0.44, 0.94) 0.02
Sum dietary EPA + DHA 0.72 (0.50, 0.94) 0.88 (0.68, 1.49) 0.04
Ratio dietary n-3/n-6 fatty acids 0.18 (0.16, 0.21) 0.21 (0.18, 0.27) 0.007
Plasma PL (g/100 g)
Plasma PL 20:4n-6 (AA) 9.2 (7.7, 10.8) 9.3 (8.0, 10.5) 0.85
Plasma PL 20:5n-3 (EPA) 1.2 (1.0, 1.7) 1.5 (1.1, 2.2) 0.30
Plasma PL 22:6n-3 (DHA) 5.4 (4.4, 6.7) 6.0 (5.0, 7.2) 0.20
Sum plasma PL EPA + DHA 6.7 (5.8, 7.7) 7.6 (6.0, 9.4) 0.17
Ratio plasma PL n-3/n-6 fatty acids 0.25 (0.18, 0.28) 0.26 (0.20, 0.35) 0.32
a
Abbreviation is as follows: PL: phospholipids.
recommendations. Dietary DHA intake was in this patient
population related to its concentration in plasma PL, tumour
tissue, and normal mucosa. Dietary intake of single n-6
PUFA, LA and AA did not correlate with its concentration in
plasma PL, tumour tissue or normal mucosa. On the other
hand, high dietary intake of EPA and DHA was reflected as
high concentrations of these fatty acids and a high ratio of n-
3/n-6 PUFA in plasma and tissues. Concentrations of n-3 and
n-6 PUFAwith chain length C20-22 (AA, EPA andDHA) and
the ratio of n-3/n-6 PUFA were higher in tumour tissue than
normal mucosa, whereas concentrations of PUFA with chain
length C18 (LA and ALA) were higher in normal mucosa.
Surprisingly, dietary DHA intake was positively related to
cancer severity measured by Duke’s stage.
The present results suggest that fatty acid metabolism
is altered in CRC patients, as indicated by earlier studies.
First, we did not find correlation between dietary intakes of
single n-6 PUFA and plasma PL concentrations of these in
CRC patients. The absence of correlation for LA between
diet and plasma PL agrees with an earlier similar finding
in FAP patients [16], but disagrees with large studies in
average, diverse adult population, which have demonstrated
a significant positive correlation between LA concentration
in plasma PL (weight%) and habitual diet assessed by FFQ
[21, 22]. Another sign of abnormal LA metabolism in
CRC in the present study was that concentration of LA in
plasma PL significantly correlated with LA concentration
in normal mucosal tissue, but not in tumour tissue. This
indicates an altered incorporation of LA from plasma PL
into tumour tissue, or increased elongation of LA into AA in
tumours. As a contrast, there were high correlations between
intake levels, plasma PL and tumour and normal mucosal
tissue concentrations for EPA and DHA in the present CRC
patient population. Such high correlations between intake
and biomarkers of these external PUFA are found in average
population [21, 22] and were expected also for LA. n-3
PUFA concentrations in plasma PL were reflected in their
concentrations in both normal mucosa and tumour tissue
in the present study. An unexplainable finding was that n-
3 PUFA concentration in plasma PL correlated also with AA
concentration in normalmucosa, and only in overweight and
not in lean patients.
The second major finding on altered fat metabolism
in CRC patients was that PUFA concentrations of CRC
tumour tissue differed from non-diseased mucosal tissue
in the present patient group; AA, EPA, and DHA were
more abundant in tumour tissue than in normal colonic
mucosa. This reflects the PUFA pattern in plasma PL found
earlier in FAP patients as compared to control subjects [16].
Similar results on increased AA and DHA concentrations in
human CRC tumours [14] and a higher concentration of
AA in rat tumour tissue [23] have been found. In contrast,
the opposite has also been found; lower AA concentration
in phospholipids extracted from human colon cancer cells
compared to normal mucosa cells [24], non-different con-
centrations of AA and DHA, and lower concentration of
EPA in human diseased versus normal mucosa [13]. The
ratio n-3/n-6 PUFA in plasma PL and tumour tissue was
in the present study correlated to dietary intake of EPA
and DHA and was higher in tumour tissue than in normal
mucosa. This suggests that EPA and DHA are incorporated
from diet into plasma and tissues in CRC patients, but
that these are particularly accumulated in tumour tissue.
The lower concentrations of ALA in tumour than normal
mucosal tissue may also suggest an increased elongation
of ALA into EPA and DHA in tumours. The markedly
increased AA concentration and lower LA concentrationmay
further indicate an increased elongation of LA into AA in
tumour tissue. Concentrations of all other measured fatty
acids were also significantly different between tumour tissue
and normal mucosa. Interpretation of differences in SFA
and MUFA concentrations is difficult and may reflect the
differences in PUFA concentrations.
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The third and most unexplainable finding of altered
PUFA metabolism in the present study was that patients
with the most advanced cancer stage reported highest dietary
intake of DHA, and ratio of dietary n-3/n-6 PUFA. However,
this difference in intake between Duke’s stage groups A + B
and C + D was not reflected in plasma PL. One reasonable
explanation might be overreporting of dietary marine n-3
PUFA intake among those with the most severe diagnosis.
The FFQ was filled by the patients up to four weeks after the
CRC diagnosis. Dietary habits may have changed after the
diagnosis, biasing reporting of average diet before the diag-
nosis. A possible true relationship between higher dietary
intake of DHA and CRC severity would be unexpected in
the light of the major evidence for a protecting effect of n-
3 PUFA in colorectal carcinogenesis [25, 26]. Animal and
cell line experiments suggest that n-3 PUFA on the contrary
may reduce colorectal tumour formation [27] and suppress
AA-induced proliferation in colon carcinoma cells [28].
There also is a plausible pathway for the anticarcinogenic
effect of n-3 PUFA through inhibiting PGE2 synthesis
and consequently reducing COX-2 expression [29, 30], an
important step in colorectal carcinogenesis. Further, there
is evidence that dietary n-3 PUFA intake protects against
inflammation in cancer patients by an effect on COX-2 levels
[31, 32]. Only very few reports of procarcinogenic effects of
n-3 PUFA can be found [33]. A possible carcinogenic effect
of dietary EPA and DHA might relate to proinflammatory
activity of these highly oxidizable fatty acids. High-dose n-3
PUFA intervention (2.5–4.8 g EPA + DHA per day) in other
patient groups has resulted in increased concentrations of
soluble inflammatory markers of endothelial function [34,
35]. These, as well as other inflammatory markers have been
related to CRC development and increasing Duke’s stage
[36–38]. The median dietary intake of EPA and DHA in the
present patient group was, however, according to national
recommendations, and only two patients reported intake
levels above 2.0 g per day. In spite of an average intake of
fatty acids as recorded by the questionnaires, overweight was
prevalent (48% of the patients with BMI≥ 25 kg/m2). Malig-
nancy at younger age may indicate genetic involvement, but
also a direct relationship between overweight and colorectal
neoplasia could be possible [39]. Nevertheless, we did not
observe higher prevalence of overweight or obesity in the
group with higher Duke’s stage. Future long term studies are
needed to confirm a possible association between intake of
high-dose n-3 PUFA intake and Duke’s stage.
Lack of a control group is a weakness of the present
study. The study would also have been strengthened by
additionally analyzing fatty acid patterns in adenomas, since
colorectal neoplasia develops over many years and the
metabolic situation in cancerous tissue is different from
that in adenomas. Further, it is unclear to what extent fatty
acid intake right before the diagnosis, as assessed in the
present study, is the critical period of intake with regard
to tumorigenesis. The most optimal study design might
therefore include dietary intake, plasma and tissue samples
from patients with colorectal adenomas, and CRC patients
and healthy controls.
5. Conclusions
The present study showed that metabolism of n-6 and n-3
PUFA was altered in young CRC patients. Dietary LA did not
correlate with its concentration in plasma PL and normal
tissue, indicating an increased elongation of LA into AA in
tumour tissue. The higher concentrations of AA, EPA and
DHA, and ratio of n-3/n-6 PUFA in colorectal tumours than
in normal mucosal tissue warrants further investigations. We
suggest that future prospective studies address the possible
relation between dietary intake of n-3 PUFA andDuke’s stage
in CRC in comparison to normal mucosa and adenomas,
both among young and old patients.
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